Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ANET$186.00+5.79(+3.53%)Arista Networks, Inc. (ANET) Q3 2026 Earnings Call Transcript11:15:53 PM ETGS$893.99-4.83(-0.54%)QUOTES-Market analysts react to US midterm election results11:10:09 PM ETAMD$508.30+17.47(+3.75%)GLOBAL MARKETS-Stocks wilt, dollar slides as early midterm results point to blue sweep10:49:47 PM ETAMGN$456.00-4.12(-0.89%)Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript10:45:58 PM ETRPG$53.54+1.07(+2.04%)RPG: This Pure Growth ETF Just Got A Whole Lot Cheaper10:42:37 PM ETANET$186.00+5.79(+3.53%)What Arista Networks (ANET) Said on Its Q3 Earnings Call10:14:51 PM ETGOOG$276.96-1.04(-0.37%)Anthropic S-1: Record Growth, but is the IPO a Buy?10:01:10 PM ETSTT$169.71+0.40(+0.24%)QUOTES-Analysts react to US midterm election results9:55:24 PM ETAMD$508.30+17.47(+3.75%)What Advanced Micro Devices (AMD) Said on Its Q3 Earnings Call9:15:33 PM ETAMZN$248.54+2.83(+1.15%)Filing: Amazon's previously announced layoffs include 95 jobs in Washington state9:11:34 PM ETAMD$508.30+17.47(+3.75%)AMD's OpenAI, Meta chip deals trigger $1 billion quarterly charge9:10:35 PM ETNKE$38.29-0.83(-2.12%)Nike vs. Procter & Gamble: Which Consumer Stock Is a Better Buy for 2027?9:00:01 PM ETNVS$159.26-2.26(-1.40%)Novartis: 3 Key Takeaways for Long-Term Investors8:27:03 PM ETGOOG$276.96-1.04(-0.37%)Should You Buy Alphabet Stock After Anthropic Raised Its Google Commitment to $121 Billion?8:23:01 PM ETAMD$508.30+17.47(+3.75%)AMD EPS: Intel's Drag Makes No Sense8:16:00 PM ETAMD$508.30+17.47(+3.75%)Advanced Micro Devices, Inc. (AMD) Q3 2026 Earnings Call Transcript8:15:53 PM ETAMGN$456.00-4.12(-0.89%)What Amgen (AMGN) Said on Its Q3 Earnings Call8:15:41 PM ETMPLX$57.70-1.22(-2.07%)Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)8:03:58 PM ETAMD$508.30+17.47(+3.75%)GLOBAL MARKETS-US stock futures dip as investors await midterm election results8:03:01 PM ETAAPL$329.82-6.69(-1.98%)Apple Readies Launch of AI-Powered Health App7:42:21 PM ETAMGN$456.00-4.12(-0.89%)Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say7:30:56 PM ETAAPL$329.82-6.69(-1.98%)Apple: 3 Key Takeaways for Long-Term Investors7:28:50 PM ETAMD$508.30+17.47(+3.75%)Here's why AMD's stock is rising — and sending a confident message about the AI trade7:17:00 PM ETAMD$508.30+17.47(+3.75%)AMD: Expensive For A Reason7:15:26 PM ET

TARS · NASDAQ

Tarsus Pharmaceuticals, Inc.

$72.62 -1.46 (-1.95%)

Company overview

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.4B
Employees
323
Headquarters
Irvine, CA
Website
tarsusrx.com
CEO
Bobak R. Azamian
Listed
October 16, 2020
P/E
-63.70
Dividend yield
0.00%

Company financials

Revenue
$535M
Gross profit
$484M
Operating income
-$50.8M
EBITDA
-$39.1M
Net income
-$48.3M
EPS
-$1.14
Total assets
$581M
Total debt
$88.7M
Gross margin
90.44%
Net margin
-9.02%
Earnings yield
-1.57%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

52.3862.5572.7182.8793.04
TARS 1D NASDAQ O74.30H75.36L70.39C72.73-0.59 (-0.80%)Vol602.72K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
TARSTarsus Pharmaceuticals, Inc. Stock news Tarsus Pharmaceuticals Q3 Earnings Call Highlights MarketBeat
TARSTarsus Pharmaceuticals, Inc. Stock news Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript Seeking Alpha
TARSTarsus Pharmaceuticals, Inc. Stock news Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Zacks Investment Research
TARSTarsus Pharmaceuticals, Inc. Stock news Tarsus Pharmaceuticals Q3 product sales jump 64%, beating estimates Reuters
TARSTarsus Pharmaceuticals, Inc. Stock news BRIEF-Tarsus Pharmaceuticals Q3 EPS USD -14.4 Reuters
TARSTarsus Pharmaceuticals, Inc. Press release Tarsus Reports Third Quarter 2026 Financial Results GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Stock news How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78% Zacks Investment Research
TARSTarsus Pharmaceuticals, Inc. Stock news My 'Eye' Is On Tarsus Pharmaceuticals Seeking Alpha
TARSTarsus Pharmaceuticals, Inc. Press release Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Press release Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Stock news Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline Zacks Investment Research
TARSTarsus Pharmaceuticals, Inc. Press release Lisata Therapeutics Appoints Jeff Farrow to Board of Directors GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Stock news Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options Seeking Alpha
TARSTarsus Pharmaceuticals, Inc. Press release Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Stock news Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis Defense World
TARSTarsus Pharmaceuticals, Inc. Press release Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Stock news 114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp Defense World
TARSTarsus Pharmaceuticals, Inc. Press release Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Press release Tarsus to Participate in Upcoming Investor Conferences GlobeNewswire
TARSTarsus Pharmaceuticals, Inc. Press release Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease GlobeNewswire
See more
FAQ

Questions about Tarsus Pharmaceuticals, Inc.

What does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
What is TARS's market cap?
Tarsus Pharmaceuticals, Inc. (TARS) is a listed stock with a live quote. The latest market cap on this page is $3.4B.
Where is Tarsus Pharmaceuticals, Inc. headquartered?
Tarsus Pharmaceuticals, Inc. is headquartered in Irvine, CA.
How do I get TARS news from the API?
Call GET /v1/news?tickers=TARS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does TARS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for TARS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the TARS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs